D1. What are the subgroups for clinical trials in
recurrent ovarian cancer? Defining patient cohorts
•
BRCA mutation status
–
The only validated genomic test to include in trials
–
A validated biomarker of response to PARPi
•
Histological subtype
–
5 subtypes with variable prognosis and response to
chemotherapy
–
Trials for different subtypes is a priority, specially for rare-
subtypes.
•
Type and outcome of prior therapy
–
Anti-angiogenic, PARPi, chemotherapy and others
–
Will help to know respose of therapy after specific prior therapy
(ie platinum responses after PARPi)
5th OCCC of the GCIG: Recurrent Disease. Ann Oncol. 2016 Dec 19
